Polysaccharide-based nanocarriers (PBNs) are the focus of extensive investigation because
of their biocompatibility, low cost, wide availability, and chemical versatility, which allow a …

Nanocarriers have been widely employed in preclinical studies and clinical trials for the
delivery of anticancer drugs. The most important causes of failure in clinical translation of …

The success of anti-cancer therapies largely depends on the ability of the therapeutics to
reach their designated cellular and intracellular target sites, while minimizing accumulation …

Passive targeting is the foremost mechanism by which nanocarriers and drug-bearing
macromolecules deliver their payload selectively to solid tumors. An important driver of …

To efficiently deliver therapeutics into cancer cells, a number of strategies have been
recently investigated. The toxicity associated with the administration of chemotherapeutic …

Tumor microvasculature is fraught with numerous physiological barriers which hinder the
efficacy of anticancer agents. These barriers include chaotic blood supply, poor tumor …

For the treatment of malignant tumors, drug nanocarriers with long blood circulation time and
ability to target the tumor microenvironment are promising therapeutic abilities. In this work …

Chemotherapy is one of the important means of tumor therapy. However, most of the anti-
tumor drugs that currently used in clinic are hydrophobic non-specific drugs, which seriously …

The treatment effect of chemotherapeutics is often impeded by nonspecific biodistribution
and limited biocompatibility. Polymeric core–shell nanocarriers (PCS NCs) composed of a …

Anticancer nanomedicine was coined to describe anticancer delivery systems such as
polymer conjugates, liposomes, micelles, and metal nanoparticles. These anticancer …